Marvel Biosciences Corp.’s Post

Marvel Biosciences Corp. is delighted to report promising interim results from our collaborative autism study conducted by the iBrain Insitute in Tours, France. A single oral dose of MB-204 restored social interaction behaviors in autism model mice, signaling a potential game-changer in therapy. Collaborating with Dr. Julie Le Merrer and Dr. Jerome Becker, the study results exceeded expectations, showing Marvel's compound MB-204's capacity to normalize social deficits and enhance behaviors. "The interim data we've seen is not just promising; it could offer a totally novel approach to treating autism,” said Dr Julie Le Merrer. “The capacity of MB-204 to normalize behavior in animal models of autism supports our theory about the A2a receptor's influence on social interactivity. We're eager to validate these results with further testing and robust statistical analysis, which is already underway and expected to conclude in the coming months." Full news release here: https://lnkd.in/gtNpnP7D #AutismResearch #MB204 #biotech #canadianbiotech #canadianbusiness #alzheimers